Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602.

Coster TS, Hoge CW, VanDeVerg LL, Hartman AB, Oaks EV, Venkatesan MM, Cohen D, Robin G, Fontaine-Thompson A, Sansonetti PJ, Hale TL.

Infect Immun. 1999 Jul;67(7):3437-43.

2.

Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers.

Katz DE, Coster TS, Wolf MK, Trespalacios FC, Cohen D, Robins G, Hartman AB, Venkatesan MM, Taylor DN, Hale TL.

Infect Immun. 2004 Feb;72(2):923-30.

3.

Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen.

Kotloff KL, Herrington DA, Hale TL, Newland JW, Van De Verg L, Cogan JP, Snoy PJ, Sadoff JC, Formal SB, Levine MM.

Infect Immun. 1992 Jun;60(6):2218-24.

4.

Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.

Ranallo RT, Thakkar S, Chen Q, Venkatesan MM.

Vaccine. 2007 Mar 8;25(12):2269-78.

PMID:
17229494
5.
6.

Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2.

Kotloff KL, Losonsky GA, Nataro JP, Wasserman SS, Hale TL, Taylor DN, Newland JW, Sadoff JC, Formal SB, Levine MM.

Vaccine. 1995 Apr;13(5):495-502.

PMID:
7639017
7.

Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh.

Rahman KM, Arifeen SE, Zaman K, Rahman M, Raqib R, Yunus M, Begum N, Islam MS, Sohel BM, Rahman M, Venkatesan M, Hale TL, Isenbarger DW, Sansonetti PJ, Black RE, Baqui AH.

Vaccine. 2011 Feb 1;29(6):1347-54. doi: 10.1016/j.vaccine.2010.10.035.

PMID:
21040694
9.

Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG.

Kotloff KL, Noriega F, Losonsky GA, Sztein MB, Wasserman SS, Nataro JP, Levine MM.

Infect Immun. 1996 Nov;64(11):4542-8.

10.

Safety and immunogenicity study of the auxotrophic Shigella flexneri 2a vaccine SFL1070 with a deleted aroD gene in adult Swedish volunteers.

Kärnell A, Li A, Zhao CR, Karlsson K, Nguyen BM, Lindberg AA.

Vaccine. 1995 Jan;13(1):88-99.

PMID:
7762285
11.

Novel self-sampling culture method to monitor excretion of live, oral Shigella flexneri 2a vaccine SC602 during a community-based phase 1 trial.

Teska JD, Coster T, Byrne WR, Colbert JR, Taylor D, Venkatesan M, Hale TL.

J Lab Clin Med. 1999 Aug;134(2):141-6.

PMID:
10444027
12.

Immunogenicity of IpaC-hybrid proteins expressed in the Shigella flexneri 2a vaccine candidate SC602.

Bârzu S, Arondel J, Guillot S, Sansonetti PJ, Phalipon A.

Infect Immun. 1998 Jan;66(1):77-82.

14.

Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.

Passwell JH, Ashkenazi S, Harlev E, Miron D, Ramon R, Farzam N, Lerner-Geva L, Levi Y, Chu C, Shiloach J, Robbins JB, Schneerson R; Israel Shigella Study Group..

Pediatr Infect Dis J. 2003 Aug;22(8):701-6.

PMID:
12913770
16.
17.

Studies with a new generation of oral attenuated shigella vaccine: Escherichia coli bearing surface antigens of Shigella flexneri.

Levine MM, Woodward WE, Formal SB, Gemski P Jr, DuPont HL, Hornick RB, Snyder MJ.

J Infect Dis. 1977 Oct;136(4):577-82.

PMID:
333041
18.

A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity.

Kotloff KL, Nataro JP, Losonsky GA, Wasserman SS, Hale TL, Taylor DN, Sadoff JC, Levine MM.

Vaccine. 1995 Nov;13(16):1488-94.

PMID:
8578831
19.

Shigella flexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans.

Kotloff KL, Noriega FR, Samandari T, Sztein MB, Losonsky GA, Nataro JP, Picking WD, Barry EM, Levine MM.

Infect Immun. 2000 Mar;68(3):1034-9.

20.

Safety and immunogenicity of the live oral auxotrophic Shigella flexneri SFL124 in adult Vietnamese volunteers.

Li A, Kärnell A, Huan PT, Cam PD, Minh NB, Trâm LN, Quy NP, Trach DD, Karlsson K, Lindberg G, et al.

Vaccine. 1993;11(2):180-9.

PMID:
8438616

Supplemental Content

Support Center